Last reviewed · How we verify
NCT06952400: Melanoma
The Registry Study of Genetic Alterations of Melanoma in Taiwan
trial in Primary Melanoma of the Extremity in 250 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | National Health Research Institutes, Taiwan |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 22 August 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2030 |
| Sites | 16 locations across Taiwan |
Conditions studied
- Primary Melanoma of the Extremity — all drugs for Primary Melanoma of the Extremity →
Sponsor
National Health Research Institutes, Taiwan
Who can join
18 and older, any sex, with Primary Melanoma of the Extremity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06952400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Health Research Institutes, Taiwan trials
Trials by the same sponsor.
- NCT07579832 — Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2 · NA · not yet recruiting
- NCT06981637 — Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Contr · Phase 2 · recruiting
- NCT07177365 — Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressiv · NA · not yet recruiting
- NCT07138261 — Taiwanese Anaplastic Thyroid Cancer Registry · not yet recruiting
- NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06952400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Health Research Institutes, Taiwan
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06952400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing